87.27
price down icon0.61%   -0.54
after-market アフターアワーズ: 87.27
loading
前日終値:
$87.81
開ける:
$88.1
24時間の取引高:
388.63K
Relative Volume:
0.54
時価総額:
$5.55B
収益:
$136.86M
当期純損益:
$-168.69M
株価収益率:
-31.06
EPS:
-2.81
ネットキャッシュフロー:
$-113.49M
1週間 パフォーマンス:
-3.76%
1か月 パフォーマンス:
+37.09%
6か月 パフォーマンス:
+51.04%
1年 パフォーマンス:
+76.95%
1日の値動き範囲:
Value
$86.75
$88.36
1週間の範囲:
Value
$86.75
$91.39
52週間の値動き範囲:
Value
$40.61
$94.80

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
名前
Rhythm Pharmaceuticals Inc
Name
セクター
Healthcare (1162)
Name
電話
857-264-4280
Name
住所
222 BERKELEY STREET, BOSTON, MA
Name
職員
283
Name
Twitter
@rhythmpharma
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
RYTM's Discussions on Twitter

RYTM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
87.27 5.79B 136.86M -168.69M -113.49M -2.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-10 開始されました Goldman Buy
2025-07-07 開始されました Leerink Partners Outperform
2025-04-07 アップグレード BofA Securities Neutral → Buy
2025-03-05 再開されました Stifel Buy
2025-01-02 開始されました Jefferies Buy
2024-12-20 開始されました Oppenheimer Outperform
2024-10-21 開始されました Guggenheim Buy
2024-09-18 開始されました H.C. Wainwright Buy
2024-09-17 開始されました JMP Securities Mkt Outperform
2024-05-08 ダウングレード BofA Securities Buy → Neutral
2023-12-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-08-01 アップグレード BofA Securities Neutral → Buy
2023-01-18 再開されました Canaccord Genuity Buy
2022-08-08 アップグレード Goldman Neutral → Buy
2022-08-05 アップグレード BofA Securities Underperform → Neutral
2022-06-17 繰り返されました Needham Buy
2022-03-02 再開されました Stifel Buy
2022-02-17 アップグレード Ladenburg Thalmann Neutral → Buy
2021-12-08 開始されました Wells Fargo Overweight
2021-11-19 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-14 再開されました Goldman Neutral
2021-08-04 ダウングレード BofA Securities Neutral → Underperform
2021-08-04 ダウングレード Ladenburg Thalmann Buy → Neutral
2020-11-30 ダウングレード BofA Securities Buy → Neutral
2020-01-08 開始されました Goldman Sell
2019-07-12 アップグレード Stifel Hold → Buy
2019-07-08 開始されました Canaccord Genuity Buy
2019-03-13 開始されました Ladenburg Thalmann Buy
2018-09-07 再開されました Morgan Stanley Overweight
2018-06-25 繰り返されました Needham Buy
2018-06-15 繰り返されました Needham Buy
2017-10-30 開始されました BofA/Merrill Buy
2017-10-30 開始されました Needham Buy
すべてを表示

Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース

pulisher
12:15 PM

Rhythm Pharmaceuticals Inc. Stock Analysis and ForecastHigh-yield growth strategies - Autocar Professional

12:15 PM
pulisher
Jul 23, 2025

Is Rhythm Pharmaceuticals Inc. a good long term investmentMarket-leading growth rates - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Rhythm Pharmaceuticals Inc. stockTremendous growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Rhythm Pharmaceuticals Inc. stock priceConsistently outstanding ROI - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Should You Invest in This Under-the-Radar Weight Loss Stock? - Yahoo Finance

Jul 21, 2025
pulisher
Jul 20, 2025

Rhythm Pharmaceuticals prices $175M stock offering - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

Why Rhythm Pharmaceuticals Inc. stock is on top investor watchlistsMoney Making Low Risk Plans - beatles.ru

Jul 19, 2025
pulisher
Jul 18, 2025

Rhythm Pharmaceuticals Q1 2025 Earnings: IMCIVREE Sales Reach $37.7M, Inventory Impact Affects Revenue, Cash on Hand Reaches $314.5M - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Rhythm Pharmaceuticals CFO Sells 42,120 Shares - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts - Nasdaq

Jul 18, 2025
pulisher
Jul 18, 2025

Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on obesity treatment potential - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

(RYTM) Investment Analysis - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 15, 2025

Rhythm Pharmaceuticals stock price target raised to $109 from $95 at BofA - Investing.com Canada

Jul 15, 2025
pulisher
Jul 13, 2025

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given a $110.00 Price Target by Oppenheimer Analysts - MarketBeat

Jul 13, 2025
pulisher
Jul 13, 2025

The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals: MC4R Agonists Poised to Transform Obesity Treatment and Drive Market Leadership - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals announces public offering of common stock - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham - MSN

Jul 13, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals' MC4R Agonists: A Rare Disease Breakthrough with Massive Upside - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals: Pioneering a New Era in Rare Obesity Therapies with MC4R Agonists - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals says Phase 2 signal trial shows bivamlegon reduces BMI in hypothalamic obesity - MarketScreener

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug - MSN

Jul 12, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals' Insider Sales: A Pre-Planned Strategy or a Signal for Investors? - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals: Insider Sales and Equity Offering Signal Mixed Signals for Investors - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals Insider Sales and I-MAB's Capital Raise: Navigating Dilution Risks and Confidence Signals - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals: Insider Selling and Valuation in a High-Stakes Biotech Landscape - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals Announces Stock Offering Agreement - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan

Jul 11, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Explores New Treatment for Hypotha - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals' Bivamelagon: A Path to Dominating Acquired Hypothalamic Obesity and Driving Stock Gains - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market (RYTM) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Gets Price Target Boost from Oppen - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals prices upsized public offering at $85 per share - Investing.com India

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Raised by B of A Secu - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com

Jul 10, 2025
pulisher
Jul 10, 2025

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data - The Globe and Mail

Jul 10, 2025
pulisher
Jul 10, 2025

Oppenheimer raises Rhythm Pharmaceuticals stock price target to $110 By Investing.com - Investing.com Canada

Jul 10, 2025

Rhythm Pharmaceuticals Inc (RYTM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Rhythm Pharmaceuticals Inc (RYTM) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Smith Hunter C
Chief Financial Officer
Jul 09 '25
Sale
80.48
42,120
3,389,756
116,915
Shulman Joseph
Chief Technical Officer
Jul 09 '25
Option Exercise
6.80
7,969
54,189
16,478
Shulman Joseph
Chief Technical Officer
Jul 09 '25
Sale
77.78
7,969
619,851
8,509
German Christopher Paul
Corporate Controller & CAO
Jul 09 '25
Option Exercise
27.29
2,850
77,786
4,739
German Christopher Paul
Corporate Controller & CAO
Jul 09 '25
Sale
80.75
3,817
308,217
922
Cramer Pamela J.
Chief Human Resources Officer
Jul 09 '25
Option Exercise
13.43
15,572
209,153
34,781
Cramer Pamela J.
Chief Human Resources Officer
Jul 09 '25
Sale
77.13
15,572
1,201,062
19,209
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
大文字化:     |  ボリューム (24 時間):